Shinshin Pharmaceutical Advances in Dementia and Parkinson's Disease Treatment Development: "Effective with Once-Weekly Application"

Transdermal drug delivery platform company Shinshin Pharmaceutical announced on the 17th that it has begun formulation research for the Alzheimer's dementia treatment ‘LA313’. Shinshin Pharmaceutical is developing a next-generation dementia treatment that significantly improves dosing intervals while minimizing the side effects of existing treatments. The commercialization of an improved drug for Parkinson's disease, another major central nervous system (CNS) disorder along with dementia, is also progressing smoothly.

Shinshin Pharmaceutical is developing a dementia treatment that can extend the dosing interval of existing treatments to one tablet every 7 days. After completing research next month to confirm the long-term release of the therapeutic drug, the company plans to proceed with ‘long-acting’ formulation research aimed at improving the dosing interval. Shinshin Pharmaceutical intends to complete the formulation research within the year and enter the non-clinical stage for LA313.

Shinshin Pharmaceutical is conducting formulation research for LA313 based on TDDS (Transdermal Drug Delivery System) technology. The goal is to commercialize an improved drug that uses multi-layer adhesive technology to ensure a consistent amount of drug absorption in the body. The company explained that it will advance the multi-layer adhesive technology during the development of LA313 and secure proprietary technology through patent applications.

At the end of last year, Shinshin Pharmaceutical also began development of the Parkinson's disease treatment ‘LA308’. Existing oral formulations have the drawback of causing gastrointestinal side effects. Shinshin Pharmaceutical plans to apply TDDS technology to improve side effects and maximize patient convenience in taking the new Parkinson's disease treatment.

A Shinshin Pharmaceutical representative stated, “Diseases related to aging such as dementia and Parkinson's make daily life difficult due to symptoms, so the dosing interval is very important. We are developing treatments for aging-related diseases that maximize dosing intervals by applying our proprietary TDDS technology, which will improve patient convenience and medication adherence.”

He added, “As aging accelerates mainly in developed countries, the market size for CNS disease treatments is rapidly growing, so the commercialization of new dementia and Parkinson's treatments is expected to have high market potential. We will secure a leading position in the aging treatment market based on brand premium for elderly patients in Korea and export references overseas.”